Showing 4291-4300 of 9578 results for "".
- Juvéderm Voluma XC Approved for Enhancement of the Chin Regionhttps://practicaldermatology.com/news/juvederm-voluma-xc-approved-for-enhancement-of-the-chin-region/2460426/The FDA has approved a new indication for Juvéderm Voluma XC for the augmentation of the chin region to improve the chin profile in adults over the age of 21. The Juvéderm Collection of Fillers has the broadest portfolio of specifically tailored treatment options, and this latest ap
- Further Evidence of Long-term Use and Cost-effectiveness of Ilumya for Psoriasis Presented at Virtual AADhttps://practicaldermatology.com/news/further-evidence-of-long-term-use-and-cost-effectiveness-of-ilumya-for-psoriasis-presented-at-virtual-aad/2460425/Sun Pharmaceutical Industries Ltd. presented further evidence of the long-term use and cost-effectiveness of tildrakizumab-asmn (Ilumya) in moderate to severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020. Long-term analyses of the reSURFA
- Dermavant Completes Enrollment for Long-Term Safety Study of Tapinarof in Adult Psoriasishttps://practicaldermatology.com/news/dermavant-completes-enrollment-for-long-term-safety-study-of-tapinarof-in-adult-psoriasis/2460416/Patient enrollment in Dermavant’s long-term safety study of tapinarof is now complete, the company says. Tapinarof is a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) being investigated for use in adult patients diagnosed with plaq
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Asana BioSciences’ JAK/SYK Inhibitor Performs Well in Phase 2b Study of Hand Eczemahttps://practicaldermatology.com/news/asana-biosciences-jaksyk-inhibitor-performs-well-in-phase-2b-study-of-hand-eczema/2460409/Asana BioSciences’ investigational oral Janus kinase family (JAK) and spleen tyrosine kinase (SYK) inhibitor gusacitinib (ASN002) showed rapid and significant improvement in a phase 2b study of 97 adult patients with moderate-to-severe chronic hand eczema. The study was a randomiz
- New Medscape Physician Compensation Report: Derms Earn About $411Khttps://practicaldermatology.com/news/new-2020-medscape-physician-compensation-report-derms-earn-about-411k/2460394/The 2020 Medscape Physician Compensation Report is out, and it shows that dermatologists earn an average of $411K per year, down 2 percent from 2019. Plastic surgeons earn $479K per year on average, up 2 percen
- Urgent: CMS Extends MIPS Extreme and Uncontrollable Circumstances Exception Application Until 4/30/2020https://practicaldermatology.com/news/urgent-cms-extends-mips-extreme-and-uncontrollable-circumstances-exception-application/2460369/The Centers for Medicare & Medicaid Services (CMS) re-opened the 2019 MIPS Extreme and Uncontrollable Circumstances Exception Application to individuals, groups, and virtual groups, including those who have already submitted data, due to the 2019 Novel Coronavirus (COVID-19) pandemi
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate
- AAD Elects New Officers, Board Membershttps://practicaldermatology.com/news/aad-elects-new-officers-board-members/2460358/Mark D. Kaufmann, MD, FAAD, has been elected to lead the American Academy of Dermatology. He will be installed as president-elect in March 2021 and hold the office of president for one year beginning in March 2022. Dr. Kaufmann, who is a member of the Practical Dermatology®
- COVID-19 By the Numbers: April 14 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-14-edition/2460346/The US may have already reached its peak for medical resource utilization associated with COVID-19, according to estimates from the Institute for Health Metrics and Evaluation (IHME), an independent population health resea